When multiple myeloma relapses

RESPOND with higher response rates with Kyprolis®-based regimen (vs Rd)

KRd overall response rate

In the ASPIRE trial, almost 9 out of 10 patients achieved a response with KRd.1

Adapted from Stewart et al.1

Kyprolis®-based regimens consistently provided benefit to relapsed multiple myeloma patients, across different measures of response1

Kyprolis® has a tolerable safety profile in combination with Rd

*Descriptive P value.

Please read the SmPC for full comprehensive safety information

References

  1. Stewart AK et al. N Engl J Med 2015;372:142–152.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis